Consensus for managing acute severe ulcerative colitis in children: A systematic review and joint statement from ECCO, ESPGHAN, and the porto IBD working group of ESPGHAN

American Journal of Gastroenterology

Volumn 106, Issue 4, 2011, Pages 574-588

  Turner, Dan ^a   Travis, Simon P L ^b   Griffiths, Anne M ^c   Ruemmele, Frank M ^d   Levine, Arie ^e   Benchimol, Eric I ^f   Dubinsky, Marla ^g   Alex, George ^h   Baldassano, Robert N ⁱ   Langer, Jacob C ^c   Shamberger, Robert ^j   Hyams, Jeffrey S ^k   Cucchiara, Salvatore ^l   Bousvaros, Athos ^j   Escher, Johanna C ^m   Markowitz, James ⁿ   Wilson, David C ^o   Van Assche, Gert ^p   Russell, Richard K ^q  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e TEL AVIV UNIVERSITY   (Israel)

^f CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h ROYAL CHILDREN'S HOSPITAL   (Australia)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j BOSTON CHILDREN S HOSPITAL   (United States)

^k UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^l SAPIENZA UNIVERSITY OF ROME   (Italy)

^m SOPHIA CHILDREN S HOSPITAL   (Netherlands)

ⁿ Northwell Health   (United States)

^o UNIVERSITY OF EDINBURGH   (United Kingdom)

^p UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^q ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CANNABINOID; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; HEPARIN; INFLIXIMAB; KETAMINE; METHYLPREDNISOLONE; METRONIDAZOLE; MORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; TACROLIMUS; TOBRAMYCIN;

ABDOMINAL PAIN; ACUTE DISEASE; ACUTE SEVERE ULCERATIVE COLITIS; ANTIBIOTIC THERAPY; CHILD; CHILDHOOD DISEASE; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RADIOGRAPHY; COLON SURGERY; CONTINUOUS INFUSION; CORTICOSTEROID THERAPY; DIARRHEA; DIET THERAPY; DISEASE SEVERITY; DRUG MONITORING; ENDOSCOPY; FECES ANALYSIS; HEALTH CARE ORGANIZATION; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOMAGNESEMIA; IMMUNE DEFICIENCY; INFECTION; INFUSION REACTION; LEISURE; NUTRITIONAL SUPPORT; PATIENT ASSESSMENT; PEDIATRIC ULCERATIVE COLITIS ACTIVITY INDEX; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCTOCOLECTOMY; PROPHYLAXIS; REVIEW; SCORING SYSTEM; SEIZURE; SIGMOIDOSCOPY; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT RESPONSE; TREMOR; ULCERATIVE COLITIS; UREMIA;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; COLITIS, ULCERATIVE; ENDOSCOPY, DIGESTIVE SYSTEM; HEPARIN; HUMANS; MESALAMINE; NUTRITIONAL SUPPORT; PALLIATIVE CARE; SEVERITY OF ILLNESS INDEX; THROMBOEMBOLISM;

EID: 79953795679     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.481     Document Type: Review

References (147)

1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; f nal report on a therapeutic trial. BMJ 1955; 2: 1041-8.
2. Travis SPL, Stange EF, L é mann M et al European evidence-based consen-sus on the management of ulcerative colitis: current management. J Crohn Colitis 2008; 2: 24-62. (Pubitemid 351179488)
3. Turner D, Otley AR, Mack D et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32. (Pubitemid 47193130)
4. Turner D, Hyams J, Markowitz J et al Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Infamm Bowel Dis 2009;15:1218-23.
5. Turner D, Walsh CM, Benchimol EI et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy Gut 2008;57:331-8. (Pubitemid 351288098)
6. Turner D, Mack DR, Leleiko N et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010; 138:2282-91.
7. Edwards FC, Truelove SC. Tecourse and prognosis of ulcerative colitis. Gut 1963;4:299-315.
8. Dinesen L, Walsh A, Cummings JRF et al Tepattern and outcome of acute severe colitis. J Crohn Colitis 2010; 4: 431-7.
9. Turner D, Walsh CM, Steinhart AH et al Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5: 103-10. (Pubitemid 46096828)
10. Turner D, Grifths AM. Acute severe ulcerative colitis in children: a sys-tematic review. Infamm Bowel Dis 2010;17:440-9.
11. Bojic D, Radojicic Z, Nedeljkovic-Protic M et al. Long-term outcome af er admission for acute severe ulcerative colitis in Oxford: the 1992-1993 cohort. Infamm Bowel Dis 2009;15:823-8.
12. Kugathasan S, Dubinsky MC, Keljo D et al Severe colitis in children. J Pediatr Gastroenterol Nutr 2005; 41: 375-85. (Pubitemid 41407596)
13. Sandhu BK, Fell JM, Beattie RM et al Guidelines for the management of inf ammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010; 50: S1-S13.
14. Wilson DC, Tomas AG, Crof NM et al Systematic review of the evidence base for the medical treatment of paediatric inf ammatory bowel disease. J Pediatr Gastroenterol Nutr 2010; 50: S14-34.
15. Bousvaros A, Antonioli DA, Colletti RB et al Dif erentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology Hepatology and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007; 44: 653-74.
16. IBD Working Group of the European Society for Paediatric Gastroenterol-ogy Hepatology and Nutrition. Inf ammatory bowel disease in children and adolescents: recommendations for diagnosis\the Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41: 1-7.
17. Rodemann JF, Dubberke ER, Reske KA et al Incidence of Clostridium dif-f cile infection in infammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:339-44. (Pubitemid 46401530)
18. Issa M, Vijayapal A, Graham MB et al Impact of Clostridium dif cile on infammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:345-51. (Pubitemid 46401531)
19. Kim J, Smathers SA, Prasad P et al Epidemiological features of Clostridium dif cile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008;122:1266-70.
20. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium dif cile in patients with inf ammatory bowel disease. Gut 2008;57:205-10. (Pubitemid 351158048)
21. Meyer AM, Ramzan NN, Lofus EV Jr et al. Tediagnostic yield of stool pathogen studies during relapses of inf ammatory bowel disease. J Clin Gastroenterol 2004;38:772-5. (Pubitemid 39274178)
22. Mylonaki M, Langmead L, Pantes A et al Enteric infection in relapse of inf ammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004;16:775-8. (Pubitemid 39062569)
23. Pascarella F, Martinelli M, Miele E et al Impact of Clostridium dif cile infection on pediatric infammatory bowel disease. J Pediatr 2009;154:854-8.
24. Markowitz JE, Brown KA, Mamula P et al. Failure of single-toxin assays to detect clostridium dif cile infection in pediatric inf ammatory bowel disease. Am J Gastroenterol 2001; 96: 2688-90.
25. Kelly CP, LaMont JT. Clostridium dif cile-more difcult than ever. N Engl JMed 2008;359:1932-40.
26. Ben-Horin S, Margalit M, Bossuyt P et al Combination immunomodulator and antibiotic treatment in patients with inf ammatory bowel disease and Clostridium dif cile infection. Clin Gastroenterol Hepatol 2009; 7: 981-7.
27. Kyne L. Clostridium difcilebeyond antibiotics. N EnglJ Med 2010;362:264-5.
28. Ayre K, Warren BF, Jefrey K et al. T e role of CMV in steroid-resistant ulcerative colitis: a systematic review. J Crohn Colitis 2009; 3: 141-8.
29. Matsuoka K, Iwao Y, Mori T et al Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol 2007;102:331-7. (Pubitemid 46160547)
30. Osaki R Andoh A, Tsujikawa T et al Acute cytomegalovirus infection superimposed on corticosteroid-naive ulcerative colitis. Intern Med 2008;47:1341-4.
31. Pfau P Kochman ML, Furth EE et al. Cytomegalovirus colitis complicat-ing ulcerative colitis in the steroid-naive patient. Am J Gastroenterol 2001;96:895-9. (Pubitemid 32240752)
32. Kambham N, Vij R, Cartwright CA et al Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study Am J Surg Pathol 2004;28:365-73. (Pubitemid 38269570)
33. Domenech E, Vega R Ojanguren I et al Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diag-nostic strategy Infamm Bowel Dis 2008;14:1373-9.
34. Papadakis KA, Tung JK, Binder SW et al Outcome of cytomegalovirus infections in patients with inf ammatory bowel disease. Am J Gastroenterol 2001;96:2137-42. (Pubitemid 32660910)
35. Travis SP, Farrant JM, Ricketts C et al Predicting outcome in severe ulcera-tive colitis. Gut 1996; 38: 905-10. (Pubitemid 26231777)
36. Seo M, Okada M, Yao T et al An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992;87:971-6.
37. Turner D, Otley AR, Mack D et al Development and evaluation of a Pedi-atric Ulcerative Colitis Activity Index (PUCAI): a prospective multicenter study Gastroenterology 2007;133:423-32. (Pubitemid 47193130)
38. Ho GT, Mowat C, Goddard CJ et al Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery Aliment Pharmacol Ter 2004;19:1079-87. (Pubitemid 38703520)
39. Turner D, Leach ST, Mack D et al Fecal calprotectin, lactoferrin, M2-pyruvate kinase, and S100A12 in severe ulcerative colitis: a prospective multicenter comparison of predicting outcomes and monitoring response. Gut 2010;59:1207-12.
40. Ho GT, Lee HM, Brydon G et al Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009;104: 673-8.
41. Rizzello F, Gionchetti P, Venturi A et al Review article: monitoring activity in ulcerative colitis. Aliment Pharmacol Ter 2002;16 (Suppl4): 3-6. (Pubitemid 34595610)
42. Carbonnel F, Lavergne A, Lemann M et al Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994;39:1550-7. (Pubitemid 24246449)
43. Maunder RG, Greenberg GR. Comparison of a disease activity index and patients ' self-reported symptom severity in ulcerative colitis. Infamm Bowel Dis 2004;10:632-6. (Pubitemid 39276473)
44. Truelove SC, Jewell DP Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 1067-70.
45. Truelove SC, Willoughby CP, Lee EG et al Further experience in the treat-ment of severe attacks of ulcerative colitis. Lancet 1978;2:1086-8. (Pubitemid 9052873)
46. Meyers S, Lerer PK, Feuer EJ et al Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 1987;9:50-4. (Pubitemid 17035259)
47. Bossa F, Fiorel la S, Caruso N et al. Continuous infusion versus bolus ad-ministration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol 2007;102:601-8. (Pubitemid 46328134)
48. Baron JH, Connell AM, Kanaghinis TG et al Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. BMJ 1962;2:441-3.
49. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison oforal pred-nisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978;13:833-7. (Pubitemid 9067125)
50. Rosenberg W Ireland A, Jewell DP High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol 1990;12:40-1. (Pubitemid 20056512)
51. Nagata S, ShimizuT, Kudo T et al. Ef cacy and safety of pulse steroid therapy in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Infammatory Bowel Disease. Digestion 2010;81:188-92.
52. Turner D, Kolho KL, Mack DR et al Glucocorticoid bioactivity does not predict response to steroid therapy in severe pediatric ulcerative colitis. Infamm Bowel Dis 2010;16:469-73.
53. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of Infamma-torybowel disease in adults. Gut 2004;53 (Suppl5): V1-V16. (Pubitemid 39120096)
54. Mantzaris GJ, Hatzis A, Kontogiannis P et al Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994;89:43-6. (Pubitemid 24020050)
55. Mantzaris GJ, Petraki K, Archavlis E et al A prospective randomized controlled trial of intravenous ciprof oxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001;36:971-4. (Pubitemid 32681462)
56. Chapman RW, Selby WS, Jewell DP Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986;27:1210-2. (Pubitemid 16002622)
57. Chande N, McDonald JW Macdonald JK. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2008:(2): CD006774.
58. Shen J, Ran ZH, Tong JL et al Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ter 2007;26:653-63. (Pubitemid 47246205)
59. Brown SR, Haboubi N, Hampton J et al. Te management of acute severe colitis: ACPGBI position statement. Colorectal Dis 2008;10 (Suppl3): 8-29.
60. Nguyen GC, Yeo EL. Prophylaxis of venous thromboembolism in IBD. Lancet 2010;375:616-7.
61. Keene DL, Matzinger MA, Jacob PJ et al Cerebral vascular events associ-ated with ulcerative colitis in children. Pediatr Neurol 2001; 24: 238-43. (Pubitemid 32294278)
62. Nguyen LT, Laberge JM, Guttman FM et al Spontaneous deep vein thrombosis in childhood and adolescence. J Pediatr Surg 1986;21:640-3. (Pubitemid 16070165)
63. Barclay AR, Keightley JM, Horrocks I et al Cerebral thromboembolic events in pediatric patients with Infammatory bowel disease. Infamm Bowel Dis 2010;16:677-83.
64. Kappelman M, Horvath-Puho E, Sandler RS et al Te association between IBD and venous thromboembolism in Danish children and adults: a popu-lation-based case-control study Gastroenterology 2010;138:S-105-6.
65. Sutherland L, Macdonald J. Oral5-aminosalicylic acid for induction of remis-sion in ulcerative colitis. Cochrane Database Syst Rev 2006: (2): CD000543.
66. Ferry GD, Kirschner BS, Grand RJ et al Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J Pediatr Gastroenterol Nutr 1993; 17: 32-8. (Pubitemid 23199287)
67. Iofel E, Chawla A, Daum F et al Mesalamine intolerance mimics symp-toms of active Infammatory bowel disease. J Pediatr Gastroenterol Nutr 2002;34:73-6. (Pubitemid 34251707)
68. Dickinson RJ, Ashton MG, Axon ATet al Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980;79:1199-204. (Pubitemid 11250460)
69. McIntyre PB, Powell-Tuck J, Wood SR et al Controlled trial ofbowel rest in the treatment of severe acute colitis. Gut 1986;27:481-5. (Pubitemid 16079746)
70. Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M et al Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 1993;88:227-32. (Pubitemid 23053475)
71. Barabino A, Tegaldo L, Castellano E et al Severe attack of ulcerative colitis in children: retrospective clinical survey Dig Liver Dis 2002;34:44-9. (Pubitemid 34202054)
72. Smith FW, Law DH, Nickel WF et al Fulminant ulcerative colitis with toxic dilatation of the colon: medical and surgical management of eleven cases with observations regarding etiology Gastroenterology 1962;42:233-43.
73. Whorwell PJ, Isaacson P. Toxic dilatation of colon in Crohn's disease. Lancet 1981;2:1334-7.
74. Benchimol EI, Turner D, Mann EH et al Toxic megacolon in children with Infammatory bowel disease: clinical and radiographic characteristics. Am J Gastroenterol 2008;103:1524-31. (Pubitemid 351826838)
75. Lowenstein O, Leyendecker P, Hopp M et al Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009;10:531-43.
76. Felder JB, Korelitz BI, Rajapakse R et al Effects of nonsteroidal antiinf am-matory drugs on Infammatory bowel disease: a case-control study Am J Gastroenterol 2000;95:1949-54.
77. Kaufmann HJ, Taubin HL. Nonsteroidal anti-Infammatory drugs activate quiescent Infammatory bowel disease. Ann Intern Med 1987; 107: 513-6. (Pubitemid 17149770)
78. Mahadevan U, Lofus EV Jr, Tremaine WJ et al Safety of selective cyclooxy-genase-2 inhibitors in infammatory bowel disease. Am J Gastroenterol 2002;97:910-4. (Pubitemid 34408247)
79. Matuk R Crawford J, Abreu MTet al Te spectrum of gastrointestinal toxicity and ef ect on disease activity of selective cyclooxygenase-2 inhibi-tors in patients with infammatory bowel disease. Infamm Bowel Dis 2004;10:352-6. (Pubitemid 39029177)
80. Reinisch W, Miehsler W, Dejaco C et al An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in Infammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ter 2003;17:1371-80. (Pubitemid 36774144)
81. Duncan MA, Spiller JA. Analgesia with ketamine in a patient with periop-erative opioid tolerance. J Pain Symptom Manage 2002;24:8-11.
82. White M, Shah N, Lindley K et al Pain management in fulminating ulcera-tive colitis. Paediatr Anaesth 2006; 16: 1148-52. (Pubitemid 44581643)
83. Fioramonti J, Bueno L. Role of cannabinoid receptors in the control of gastrointestinal motility and perception. Expert Rev Gastroenterol Hepatol 2008;2:385-97.
84. Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in Infammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil 2006; 18: 949-56. (Pubitemid 44358865)
85. Storr MA, Yuce B, Andrews CN et al Te role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterol Motil 2008;20:857-68. (Pubitemid 352022722)
86. Jakobovits SL, Travis SP. Management of acute severe colitis. Br Med Bull 2006;75-76:131-44. (Pubitemid 44725920)
87. Werlin SL, Grand RJ. Severe colitis in children and adolescents: diagnosis. Course, and treatment. Gastroenterology 1977;73:828-32. (Pubitemid 8210086)
88. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology Practice Parameters Com-mittee. Am J Gastroenterol 2004; 99: 1371-85. (Pubitemid 39062279)
89. Seo M, Okada M, Yao Tet al Evaluation of the clinical course of acute at-tacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol 2002;37:29-34. (Pubitemid 34144959)
90. Lindgren SC, Flood LM, Kilander AF et al Early predictors of glucocor-ticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10: 831-5. (Pubitemid 28493257)
91. Jarnerot G, Hertervig E, Friis-Liby I et al Inf iximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-con-trolledstudy Gastroenterology 2005;128:1805-11. (Pubitemid 40824691)
92. Benchimol EI, Turner D, Mann EH et al Toxic megacolon in children with Infammatory bowel disease: clinical and radiographic characteristics. Am J Gastroenterol 2008;103:1524-31. (Pubitemid 351826838)
93. Cunsolo A, Bragaglia RB, Arena N et al Toxic megacolon complicating ulcerative colitis and Crohn's disease. Int Surg 1985; 70: 339-43. (Pubitemid 16102666)
94. Hartong WA, Arvanitakis C, Skibba RM et al Treatment of toxic mega-colon. A comparative review of 29 patients. Am J Dig Dis 1977; 22: 195-200. (Pubitemid 8082987)
95. Igarashi C, Hori T, Yoshida M et al Acute fulminant ulcerative colitis with toxic megacolon. Acta Paediatr Jpn 1997;39:237-40. (Pubitemid 27166500)
96. Katzka I, Katz S, Morris E. Management of toxic megacolon: the signif-cance of early recognition in medical management. J Clin Gastroenterol 1979;1:307-11. (Pubitemid 11215549)
97. Miller AD. Radiographic evaluation of toxic megacolon in acute ulcerative colitis. J Am Osteopath Assoc 1972;71:1089-92.
98. Nicholls S, Vieira MC, Majrowski WH et al Linear growth af er colectomy for ulcerative colitis in childhood. J Pediatr Gastroenterol Nutr 1995;21:82-6.
99. Scepanovic D, Perisic V, Petrovic M. Long-term study of children with ulcerative colitis. Hellenic J Gastroenterol 1996; 9: 312-6. (Pubitemid 28486456)
100. White M, Shah N, Lindley K et al Pain management in fulminating ulcerative colitis. Paediatr Anaesth 2006;16:1148-52. (Pubitemid 44581643)
101. OrkinBA,TelanderRL, WolfBGet al. Te surgical management of children with ulcerative colitis. Te old vs. the new Dis Colon Rectum 1990;33:947-55. (Pubitemid 20381643)
102. Jalan KN, Sircus W, Card WI et al An experience of ulcerative colitis. I. Toxic dilation in 55 cases. Gastroenterology 1969;57:68-82.
103. Strauss RJ, Flint GW, Platt N et al Te surgical management of toxic dila-tation of the colon: a report of 28 cases and review of the literature. Ann Surg 1976;184:682-8.
104. Present DH, Wolfson D, Gelernt IM et al Medical decompression of toxic megacolon by " rolling ". A new technique of decompression with favorable long-term follow-up. J Clin Gastroenterol 1988; 10: 485-90.
105. Chao HC, Chiu CH, Kong MS et al Factors associated with intestinal perforation in children's non-typhi Salmonella toxic megacolon. Pediatr Infect Dis J 2000;19:1158-62.
106. Castro Fernandez M, Garcia Romero D, Sanchez Munoz D et al. [Severe ulcerative colitis, with toxic megacolon, resolved with infiximab therapy]. Rev Esp Enferm Dig 2007; 99: 426-7.
107. Shibolet O, Regushevskaya E, Brezis M et al Cyclosporine A for induc-tion of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005:(1): CD004277.
108. Sternthal MB, Murphy SJ, George J et al Adverse events associated with the use of cyclosporine in patients with infammatorybowel disease. Am J Gastroenterol 2008;103:937-43. (Pubitemid 351501092)
109. Actis GC, Aimo G, Priolo G et al Effcacy and effciency of oral mi-croemulsion cyclosporin versus intravenous and sof gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Infamm Bowel Dis 1998;4:276-9. (Pubitemid 128699866)
110. Lichtiger S, Present DH, Kornb luth A et al Cyclosporine in severe ulcera-tive colitis refractoryto steroid therapy N Engl J Med 1994;330:1841-5. (Pubitemid 24188135)
111. D'Haens G, Lemmens L, Geboes K et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcera-tive colitis. Gastroenterology 2001;120:1323-9. (Pubitemid 32322305)
112. Van Assche G, Vermeire S, Rutgeerts P. Treatment of severe steroid refrac-tory ulcerative colitis. World J Gastroenterol 2008;14:5508-11.
113. Castro M, Papadatou B, Ceriati E et al Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis. Langen-becks Arch Surg 2007;392:161-4. (Pubitemid 46328683)
114. Ogata H, Matsui T, Nakamura M et al A randomised dose f nding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255-62. (Pubitemid 44277355)
115. Hare NC, Arnott ID, Satsangi J. Terapeutic options in acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol 2008;2:357-70.
116. Schwartz M, Cohen R Optimizing conventional therapy for Infammatory bowel disease. Curr Gastroenterol Rep 2008;10:585-90.
117. Ziring DA, Wu SS, Mow WS et al Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2007;45:306-11. (Pubitemid 47415081)
118. Navas Lopez VM, Blasco Alonso J, Sierra Salinas C et al [Safety and ef-cacy of oral tacrolimus in the treatment of paediatric Infammatory bowel disease]. An Pediatr (Barc) 2009;70:519-25.
119. Bousvaros A, Kirschner BS, Werlin SL et al Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000;137:794-9.
120. Hyams JS, Lerer T, Grifths AM et al Outcome following inf ixi-mab therapy in children with ulcerative colitis. Am J Gastroenterol 2010; 105: 1430-6.
121. Kohn A, Daperno M, Armuzzi A et al. Inf iximab in severe ulcerative colitis: short-term results of dif erent infusion regimens and long-term follow-up. Aliment Pharmacol Ter 2007;26:747-56. (Pubitemid 47246204)
122. Ferrante M, Vermeire S, Katsanos KH et al Predictors of early response to inf iximab in patients with ulcerative colitis. Infamm Bowel Dis 2007;13:123-8. (Pubitemid 46806219)
123. Maser EA, Deconda D, Lichtiger S et al Cyclosporine and inf iximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008; 6: 1112-6.
124. Leblanc S, Allez M, Seksik P et al Successive treatment with cyclosporine and inf iximab of severe ulcerative colitis. Gut 2008; 57: A66.
125. Manosa M, Lopez San Roman A, Garcia-Planella E et al Inf iximab rescue therapy af er cyclosporin failure in steroid-refractory ulcerative colitis. Digestion 2009;80:30-5.
126. Herrlinger KR, Barthel DN, Schmidt KJ et al Inf iximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Aliment Pharmacol Ter 2010;31:1036-41.
127. de Montbrun SL, Johnson PM. Proximal diversion at the time of ileal pouch-anal anastomosis for ulcerative colitis: current practices of North American colorectal surgeons. Dis Colon Rectum 2009;52:1178-83.
128. Nicholls RJ, Holt SD, Lubowski DZ. Restorative proctocolectomy with ileal reservoir. Comparison of two-stage vs. three-stage procedures and analysis of factors that might af ect outcome. Dis Colon Rectum 1989; 32: 323-6. (Pubitemid 19104326)
129. Weston-Petrides GK, Lovegrove RE, Tilney HS et al. Comparison of outcomes af er restorative proctocolectomy with or without defunctioning ileostomy Arch Surg 2008;143:406-12. (Pubitemid 351574871)
130. Sako M, Kimura H, Arai K et al Restorative proctocolectomy for pediatric patients with ulcerative colitis. Surg Today 2006;36:162-5. (Pubitemid 43163400)
131. Galandiuk S, Wolf BG, Dozois RR et al Ileal pouch-anal anastomosis without ileostomy Dis Colon Rectum 1991;34:870-3.
132. Tjandra JJ, Fazio VW, Milsom JW et al Omission of temporary diver-sion in restorative proctocolectomy\is it safe? Dis Colon Rectum 1993;36:1007-14. (Pubitemid 23335246)
133. Tilney HS, Constantinides V, Ioannides AS et al. Pouch-anal anastomosis vs straight ileoanal anastomosis in pediatric patients: a meta-analysis. J Pediatr Surg 2006; 41: 1799-808. (Pubitemid 44709066)
134. Seetharamaiah R, West BT, Ignash SJ et al Outcomes in pediatric patients undergoing straight vs J pouch ileoanal anastomosis: a multicenter analy-sis. J Pediatr Surg 2009;44:1410-7.
135. da Luz Moreira A, Kiran RP, Lavery I. Clinical outcomes ofileorectal anastomosis for ulcerative colitis. Br J Surg 2010;97:65-9.
136. Cornish JA, Tan E, Teare J et al Te effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum 2007; 50: 1128-38. (Pubitemid 47087474)
137. Pakarinen MP, Natunen J, Ashorn M et al. Long-term outcomes of restorative proctocolectomy in children with ulcerative colitis. Pediatrics 2009;123:1377-82.
138. Mortier PE, GambiezL, KarouiM et al. Colectomy with ileorectal anas-tomosis preserves female fertility in ulcerative colitis. Gastroenterol Clin Biol 2006;30:594-7.
139. Uchino M, Ikeuchi H, Matsuoka H et al Risk factors associated with sur-gical site infection af er ileal pouch-anal anastomosis in ulcerative colitis. Dis Colon Rectum 2010; 53: 143-9.
140. Ferrante M, D'Hoore A, Vermeire et al Corticosteroids but not inf-liximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Infamm Bowel Dis 2009;15:1062-70.
141. Mahadevan U, Lofus EV Jr, Tremaine WJ et al Azathioprine or 6-mer-captopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Infamm Bowel Dis 2002;8:311-6.
142. Mor IJ, Vogel JD, da Luz Moreira A et al. Inf iximab in ulcerative colitis is as-sociated with an increased risk of postoperative complications af er restorative proctocolectomy Dis Colon Rectum 2008;51:1202-7; discussion 1207-10.
143. Kunitake H, Hodin R, Shellito PC et al Perioperative treatment with inf-liximab in patients with Crohn's disease and ulcerative colitis is not associ-ated with an increased rate of postoperative complications. J Gastrointest Surg 2008;12:1730-6; discussion 1736-7.
144. Selvasekar CR Cima RR, Larson DW et al Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007;204:956-62; discussion 962-3. (Pubitemid 46661200)
145. Schluender SJ, Ippoliti A, Dubinsky M et al Does inf iximab inf uence sur-gical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 2007; 50: 1747-53. (Pubitemid 350077092)
146. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advi-sory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004;38:1706-15. (Pubitemid 38781662)
147. Kader HA, Mascarenhas MR Piccoli DA et al. Experiences with 6-mer-captopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999;28:54-8. (Pubitemid 29292876)